Final One (4 of 4) -- Here Is Amgen's Q1 2025 Lobby Spending, By Buckets...

This California company is at the forefront of bio-science, and so it needs to constantly educate the Congress. . . on why its research and development spends are vital to the future of American health and wellness. And it is forever trying to minimize its tax bill -- since it is so wildly profitable, globally.

It almost always (over the last decade, at least) comes in second, behind only Pfizer, year after year, in spending on bending the ear of government -- about health care and tax topics. Now you know:

. . .Issues related to drug pricing reform -- Changes to Public law 117-1769 Inflation Reduction Act, and Awareness of implications to patients and research and development of Public law 117-1769 in Inflation Reduction Act. . . .

Issues related to cardiovascular disease awareness and treatment; Issues related to FDA; Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters; Issues related to biosimilars reimbursement; Issues related to Supply Chain; Issues related to 340B; Issues related to pharmacy benefit managers; Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions; Issues related to prohibiting the export of biotechnology to certain foreign entities (BIOCOMPETE); Issues related to direct-to-consumer advertising; Issues related to obesity disease awareness and treatment; Issues related to biosimilars regulatory standards; Issues related to bone disease awareness and treatment; Issues related to pediatric priority review voucher reauthorization; HR 946 Optimizing Research Progress Hope and New Cures Act; HR 1492 Insuring Pathways to Innovative Cures Act; HR 1672 Maintaining Investments in New Innovation Act; HR 2214 DRUG Act. . . .

H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025. . . .

S.Con.Res.7 - An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. . . .

H.Con.Res.14 - Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. . . .

Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act; Issues related to Puerto Rico; Issues related to OECD negotiations on the taxation of global income; HR 1328 Supply Chain Security and Growth Act of 2025. . . .

Federal Trade Commission related issues, no specific bill; Issues related to the Patent Act, no specific bill; Issues related to March-In/Bayh Dole, WTO/TRIPS waiver, no specific bill; Issues related to patent thickets/product hopping; Issues related to obviousness/ double patenting; Issues related to prohibiting the export of biotechnology to certain foreign entities (BIOCOMPETE); Issues related to FDA/PTO coordination; Issues related to skinny labeling; S.1041 A bill to amend title 35, United States Code, to address the infringement of patients that claim biological products, and for other purposes; S.1040 A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. . . .

Issues related to tariffs. . . .

Now you know -- but of course, Tangerine 2.0's obsession with tariffs. . . is resulting in vastly wasted corporate assets inside the US -- as executives and policy wonks try to discern whether he actually has any concrete policy goals in mind -- at all. . . or is it all just a "randomw walk" -- through Pete Navarro's addled frontal lobes. Yikes.

नमस्ते